BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zhen S, Qiang R, Lu J, Tuo X, Yang X, Li X. Enhanced antiviral benefit of combination therapy with anti-HBV and anti-PD1 gRNA/cas9 produces a synergistic antiviral effect in HBV infection. Mol Immunol 2021;130:7-13. [PMID: 33340931 DOI: 10.1016/j.molimm.2020.12.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Pandey M, Ojha D, Bansal S, Rode AB, Chawla G. From bench side to clinic: Potential and challenges of RNA vaccines and therapeutics in infectious diseases. Mol Aspects Med 2021;:101003. [PMID: 34332771 DOI: 10.1016/j.mam.2021.101003] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
2 Ohsaki E, Suwanmanee Y, Ueda K. Chronic Hepatitis B Treatment Strategies Using Polymerase Inhibitor-Based Combination Therapy. Viruses 2021;13:1691. [PMID: 34578273 DOI: 10.3390/v13091691] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Ramirez-Phillips AC, Liu D. Therapeutic Genome Editing and In Vivo Delivery. AAPS J 2021;23:80. [PMID: 34080099 DOI: 10.1208/s12248-021-00613-w] [Reference Citation Analysis]
4 Zampogiannis A, Piperi C, Baka M, Zoi I, Papavassiliou AG, Moschovi M. Low IL-23 levels in peripheral blood and bone marrow at diagnosis of acute leukemia in children increased with the elimination of leukemic burden. J Cell Mol Med 2021;25:7426-35. [PMID: 34235838 DOI: 10.1111/jcmm.16772] [Cited by in F6Publishing: 1] [Reference Citation Analysis]